Positive RUBY phase III data show potential for Jemperli combinations
First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly
GSK`s cancer drug combination meets primary goal in late-stage trial
GSK’s Jemperli plus chemotherapy approved as the first and only
GSK`s cancer drug Jemperli meets overall survival goal in late-stage trial
ESMO: Jemperli appears to show survival edge over Keytruda
GSK highlights new data in non-small cell lung cancer at ESMO Congress 2023
GSK has won the first FDA approval for an immunotherapy to treat certain patients with newly diagnosed endometrial cancer. But the industry-first go-ahead is tempered with a label limitation.
GSK`s Biologic Jemperli (dostarlimab) Receives Approval in the U.S.
The biotech currently has two AAV platforms, one using DNA recombination and another that trans-splices proteins, with treatment targets in ophthalmology. AAVantgarde is seeking to validate its two lead platforms, tagging the funds for a proof-of-concept study and further development.